Literature DB >> 24828977

Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach.

Michael Paul1, Josef Ippisch, Christian Herrmann, Susanne Guber, Wolfgang Schultis.   

Abstract

The development of a liquid chromatography high-resolution mass spectrometry quadrupole-time-of-flight (LC-HRMS-QTOF) method for the analysis of new stimulant designer drugs (e.g. phenethylamine, amphetamine, cathinone and piperazine derivatives) and common drugs of abuse (e.g. ketamine and ritalinic acid) in urine is reported. Sample preparation was carried out by a fast and convenient salting-out liquid-liquid extraction (SALLE) procedure. The data was generated by a preferred target list combined with untargeted data-dependent acquisition recording additional sample information (i.e. not listed metabolites of target compounds or not database-stored drugs). The identification is realised by a fully automated data extraction algorithm, taking into account accurate mass spectra, fragment masses and retention times. Method validation comprised selectivity, linearity, accuracy, stability, determination of the limit of detection (LOD) and limit of quantification (LOQ) and evaluation of matrix effects and recoveries for a total set of 39 compounds. Acceptable quantitative results were obtained for 35 of the 39 analytes. Exemplarily, application of the additional untargeted data-dependent acquisition mode enabled the identification of metabolites of the preferred target list compounds ketamine and methylenedioxypyrovalerone (MDPV) without use of reference standards. Therefore, improvement of the database is feasible with every positive library hit. The approach presented here provides a very useful tool for the combined targeted and untargeted analysis of drugs of abuse in biological matrices such as urine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24828977     DOI: 10.1007/s00216-014-7825-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  7 in total

1.  Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching.

Authors:  Marta Concheiro; Marisol Castaneto; Robert Kronstrand; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2015-04-08       Impact factor: 4.759

2.  Enantioseparation and Determination of Mephedrone and Its Metabolites by Capillary Electrophoresis Using Cyclodextrins as Chiral Selectors.

Authors:  Pavel Řezanka; Denisa Macková; Radek Jurok; Michal Himl; Martin Kuchař
Journal:  Molecules       Date:  2020-06-23       Impact factor: 4.411

3.  3,4-Methylenedioxypyrovalerone (MDPV) Sensing Based on Electropolymerized Molecularly Imprinted Polymers on Silver Nanoparticles and Carboxylated Multi-Walled Carbon Nanotubes.

Authors:  Rosa A S Couto; Constantino Coelho; Bassim Mounssef; Sara F de A Morais; Camila D Lima; Wallans T P Dos Santos; Félix Carvalho; Cecília M P Rodrigues; Ataualpa A C Braga; Luís Moreira Gonçalves; M Beatriz Quinaz
Journal:  Nanomaterials (Basel)       Date:  2021-02-01       Impact factor: 5.076

4.  Development of an Electrochemical Sensor Using a Modified Carbon Paste Electrode with Silver Nanoparticles Capped with Saffron for Monitoring Mephedrone.

Authors:  Georgios Christos Papaioannou; Sophia Karastogianni; Stella Girousi
Journal:  Sensors (Basel)       Date:  2022-02-18       Impact factor: 3.576

5.  Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs.

Authors:  Anna Welz; Marcin Koba; Piotr Kośliński; Joanna Siódmiak
Journal:  J Clin Med       Date:  2022-03-22       Impact factor: 4.241

6.  Approaches for assessing performance of high-resolution mass spectrometry-based non-targeted analysis methods.

Authors:  Christine M Fisher; Katherine T Peter; Seth R Newton; Andrew J Schaub; Jon R Sobus
Journal:  Anal Bioanal Chem       Date:  2022-07-07       Impact factor: 4.478

7.  Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.

Authors:  Anna Welz; Marcin Koba; Piotr Kośliński; Joanna Siódmiak
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.